Considering the inherent role of (R)-CRZ as an RTK inhibitor, this discovery expands its potential clinical applications by simultaneously inhibiting cancer cell proliferation through RTK inhibition and promoting anti-tumor immunity by alleviating ferroptosis-induced stress in CD8+ T cells. The gene discussed is CD8A; the disease is cancer.